Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: apx-3330 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 391 | 0.85 |
| pathways Reactome | 6 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 8313
Sealed predictions
- APEX1 in dopamine neurons, braak+0.46 (p 0.214) → +0.28 (p 0.472)receipt 8320
Swarm cases
receipt 8320: APEX1 in dopamine neurons, braak
- power
- full sample +0.36 (p 0.137, n 18), 95% CI -0.12 to +0.71. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.34 (p 0.170, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.39 (p 0.107, n 18). could be the mix.
- skeptic
- leave-one-out range +0.29 to +0.43, sign flips 0; without severely affected donors +0.36 (p 0.137, n 18). fragile.
- cell type
- strongest in microglia: +0.64 (p 0.0040, n 18) vs +0.36 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for APEX1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up APEX1 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.38 p 0.183 (needs p < 2.6e-4)
Receipts
loading the receipts